Simulations Plus (NASDAQ:SLP) issued its earnings results on Sunday. The technology company reported $0.12 EPS for the quarter, beating the Zacks’ consensus estimate of $0.11 by $0.01, MarketWatch Earnings reports. Simulations Plus had a return on equity of 24.44% and a net margin of 22.96%.
NASDAQ:SLP traded down $6.49 during trading hours on Tuesday, reaching $72.84. The company had a trading volume of 18,722 shares, compared to its average volume of 287,831. The firm has a market cap of $1.45 billion, a PE ratio of 152.38, a price-to-earnings-growth ratio of 7.63 and a beta of -0.17. The business’s 50 day moving average price is $65.06 and its 200-day moving average price is $65.43. Simulations Plus has a 1-year low of $26.00 and a 1-year high of $83.78.
In other news, CEO Shawn Oconnor sold 5,500 shares of the company’s stock in a transaction that occurred on Monday, November 23rd. The stock was sold at an average price of $56.25, for a total transaction of $309,375.00. Following the completion of the transaction, the chief executive officer now directly owns 6,381 shares of the company’s stock, valued at approximately $358,931.25. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director David L. Ralph sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, November 30th. The stock was sold at an average price of $55.65, for a total value of $278,250.00. Following the transaction, the director now directly owns 16,581 shares of the company’s stock, valued at $922,732.65. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 64,881 shares of company stock valued at $4,347,992. Corporate insiders own 31.57% of the company’s stock.
A number of brokerages recently commented on SLP. Zacks Investment Research lowered Simulations Plus from a “hold” rating to a “sell” rating in a research report on Thursday, November 19th. Craig Hallum lowered Simulations Plus from a “buy” rating to a “hold” rating in a research report on Tuesday. Raymond James began coverage on Simulations Plus in a report on Friday, October 16th. They issued an “outperform” rating and a $95.00 price target for the company. TheStreet raised Simulations Plus from a “c+” rating to a “b” rating in a report on Friday. Finally, Taglich Brothers raised Simulations Plus from a “speculative buy” rating to a “buy” rating and set a $76.00 price target for the company in a report on Wednesday, November 25th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $81.60.
Simulations Plus Company Profile
Simulations Plus, Inc develops drug discovery and development software for mechanistic modeling and simulation, and prediction of properties of molecules utilizing artificial-intelligence- and machine-learning-based technology worldwide. The company offers GastroPlus, which simulates the absorption, pharmacokinetics (PK), pharmacodynamics, and drug-drug interactions of compounds administered to humans and animals; DDDPlus that simulates in vitro laboratory experiments; and MembranePlus, which simulates laboratory experiments.
Featured Story: What is a Futures Contract?
Receive News & Ratings for Simulations Plus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Simulations Plus and related companies with MarketBeat.com's FREE daily email newsletter.